Granulomatosis with polyangiitis medical therapy: Difference between revisions

Jump to navigation Jump to search
Line 53: Line 53:


In severe disease not responsive to previously mentioned treatment, the review is positive about [[mycophenolate mofetil]], 15-deoxyspergualin, [[anti-thymocyte globulin]], [[rituximab]] and [[infliximab]]; data was less favourable for [[intravenous immunoglobulin]] (IVIG) and [[etanercept]].<ref name="Bosch" />
In severe disease not responsive to previously mentioned treatment, the review is positive about [[mycophenolate mofetil]], 15-deoxyspergualin, [[anti-thymocyte globulin]], [[rituximab]] and [[infliximab]]; data was less favourable for [[intravenous immunoglobulin]] (IVIG) and [[etanercept]].<ref name="Bosch" />
===Methotrexate===
Methotrexate has been studied at NIH for the treatment of Wegener's granulomatosis since 1990. In people with active, but not immediately life threatening, Wegener's granulomatosis, methotrexate has been used in combination with prednisone to bring about remission. It also is used to maintain remission after a person has initially received cyclophosphamide. Methotrexate is usually given for 1 to 2 years, after which time if people stay in remission, it is decreased and stopped.
Methotrexate is given once a week usually by mouth, but occasionally as an injection under the skin or in the muscle. People taking methotrexate need to have regular blood work to monitor their response and to watch for side effects.
The side effects of methotrexate include infection, lowering of the blood counts, nausea, soreness and ulceration of the mouth lining, irritation of the lungs (pneumonitis), and inflammation and scarring of the liver. People taking methotrexate cannot drink alcoholic beverages. Methotrexate cannot be given to people who have poor kidney function or who have underlying liver disease such as hepatitis.


===Azathioprine===
===Azathioprine===

Revision as of 23:18, 10 April 2018

Granulomatosis with polyangiitis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Granulomatosis with polyangiitis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Granulomatosis with polyangiitis medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Granulomatosis with polyangiitis medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Granulomatosis with polyangiitis medical therapy

CDC on Granulomatosis with polyangiitis medical therapy

Granulomatosis with polyangiitis medical therapy in the news

Blogs on Granulomatosis with polyangiitis medical therapy

Directions to Hospitals Treating Granulomatosis with polyangiitis

Risk calculators and risk factors for Granulomatosis with polyangiitis medical therapy

Overview

In most cases, treatment consists of a combination of a glucocorticoid (a steroid) and a cytotoxic medicine. Although these medicines are helpful in treating Wegener's granulomatosis, people and their doctors should be aware that they potentially have serious side effects. In many instances these can be minimized or prevented by careful monitoring by both the doctor and patient.

Medical Therapy

Before steroid treatment became available, mortality within one year was over 90%, with average survival being 5 months. Steroids prolonged average survival to 8 months. The introduction of cyclophosphamide (CYC) in the 1970s was a major breakthrough.[1][2]

Initial treatment

Immunosuppressants

Glucocorticoids
  • Parenteral regimen (pulse therapy)
    • Preferred regimen (1):Methylprednisolone 7-15 mg/kg IV q24h for 3 days (maximum, 500-1000 mg/kg/day)
  • Oral regimen (follows parenteral pulse therapy)
    • Preferred regimen (1): Prednisone 1 mg/kg/day PO from Day 1 (maximum, 60-80 mg/day) tapered over 14 days with maximum of 20 mg/day
Cyclophosphamide
Rituximab
  • Parenteral regimen
    • Preferred regimen (1): Rituximab 375 mg/m2 IV q1week for 4 doses
    • Alternative regimen (1): Rituximab 1g IV q2weekly for 2 doses
Methotrexate
  • Parenteral regimen[3]
    • Preferred regimen (1): Methotrexate 7.5 mg q1weekly till 1 year or remission.
  • It is used in patients without any end organ damage and no life threatening disease.[4]
  • Relapse rate are higher with Methotrexate.[5]
  • Patients using methotrexate should also receive glucocorticoids.
Azathioprine
    • . Once remission is attained (normally 3 to 6 months), treatment is frequently changed to azathioprine or methotrexate, which are less toxic drugs. Total duration of therapy should be at least one year, or longer in high risk patients. Corticosteroids are tapered to a low maintenance dose, 5-10 mg/day. Plasmapheresis may be beneficial in severe disease or pulmonary hemorrhage. Experience with other treatment agents is very limited.

Some guidelines for which drug to choose.[1]

  • In localized disease, treatment with the antibiotic co-trimoxazole is recommended, with steroids in case of treatment failure.[6]
  • In generalized non-organ threatening disease, remission can be induced with methotrexate and steroids, where the steroid dose is reduced after a remission has been achieved and methotrexate used as maintenance.
  • In case of organ-threatening disease, pulsed intravenous cyclophosphamide with steroids is recommended. Once remission has been achieved, azathioprine and steroids can be used to maintain remission.
  • In severe renal vasculitis, the same regimen is used but with the addition of plasma exchange.
  • In pulmonary hemorrhage, high doses of cyclophosphamide with pulsed methylprednisolone may be used, or alternatively CYC, steroids, and plasma exchange.

In severe disease not responsive to previously mentioned treatment, the review is positive about mycophenolate mofetil, 15-deoxyspergualin, anti-thymocyte globulin, rituximab and infliximab; data was less favourable for intravenous immunoglobulin (IVIG) and etanercept.[1]

Azathioprine

Azathioprine (also called Imuran) is used primarily to maintain remission in people who have initially been treated and gone into remission with cyclophosphamide. It is taken once a day by mouth. Similar to methotrexate, it is usually given for 1 to 2 years after which time the dosage is lowered until it is stopped.

The side effects of azathioprine include infection, lowering of the blood counts, and rarely an allergic type reaction. In people who receive azathioprine to prevent rejection of a transplanted organ, there has been a suggestion of an increased risk of blood cancers (leukemia and lymphoma) but it is not clear whether this risk exists in other situations. People with poor kidney function or liver disease can take azathioprine.

Other medicines

During the course of treating Wegener's granulomatosis, doctors often give their patients other medicines to prevent medicine-related side effects. These include

  • Trimethoprim/sulfamethoxazole (also called bactrim or septra) is given three times a week to prevent Pneumocystis carinii infection (a lung infection)
  • A medicine regimen is often given to prevent prednisone-related bone loss (osteoporosis)
  • Folic acid or folinic acid (also called leucovorin) are often given to people taking methotrexate

References

  1. 1.0 1.1 1.2 Bosch X, Guilabert A, Espinosa G, Mirapeix E (2007). "Treatment of antineutrophil cytoplasmic antibody associated vasculitis: a systematic review". JAMA. 298 (6): 655–69. doi:10.1001/jama.298.6.655. PMID 17684188.
  2. Flossmann O, Berden A, de Groot K, Hagen C, Harper L, Heijl C, Höglund P, Jayne D, Luqmani R, Mahr A, Mukhtyar C, Pusey C, Rasmussen N, Stegeman C, Walsh M, Westman K (March 2011). "Long-term patient survival in ANCA-associated vasculitis". Ann. Rheum. Dis. 70 (3): 488–94. doi:10.1136/ard.2010.137778. PMID 21109517.
  3. Specks U (August 2005). "Methotrexate for Wegener's granulomatosis: what is the evidence?". Arthritis Rheum. 52 (8): 2237–42. doi:10.1002/art.21146. PMID 16052540.
  4. Langford CA, Talar-Williams C, Sneller MC (August 2000). "Use of methotrexate and glucocorticoids in the treatment of Wegener's granulomatosis. Long-term renal outcome in patients with glomerulonephritis". Arthritis Rheum. 43 (8): 1836–40. doi:10.1002/1529-0131(200008)43:8<1836::AID-ANR20>3.0.CO;2-R. PMID 10943874.
  5. De Groot K, Rasmussen N, Bacon PA, Tervaert JW, Feighery C, Gregorini G, Gross WL, Luqmani R, Jayne DR (August 2005). "Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis". Arthritis Rheum. 52 (8): 2461–9. doi:10.1002/art.21142. PMID 16052573.
  6. Stegeman CA, Tervaert JW, de Jong PE, Kallenberg CG (1996). "Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group". N. Engl. J. Med. 335 (1): 16–20. PMID 8637536.

Template:WikiDoc Sources